Cancer Drug Makers Demand 50% Price Hike on Platinum Costs

Domestic pharmaceutical companies are warning that soaring platinum prices are making the production of critical cancer drugs economically unsustainable. Manufacturers of medicines such as carboplatin and cisplatin are now formally requesting the National Pharmaceutical Pricing Authority (NPPA) to authorize a 50% increase in their maximum retail prices. The unprecedented rise in platinum, a key raw material for these platinum-based chemotherapeutics, has sharply escalated manufacturing costs. Companies state that without this significant price adjustment, the continued supply of these essential treatments is at serious risk. The NPPA is now evaluating the request, which follows a period of extreme volatility in global platinum markets.